(IN BRIEF) Novonesis has signed an agreement with TurtleTree to scale, manufacture and commercialize TurtleTree’s precision-fermented lactoferrin LF+®. Under the partnership, Novonesis will exclusively support LF+® for the early life nutrition market and will also receive selected commercial rights for … Read the full press release
Posted in Business, Denmark, Food & Beverage, Healthcare, Investment, Pharma & Biotech, Technology
Tagged 321Catalyst Ventures, biosolutions, Copenhagen, dairy proteins, Denmark, dietary supplements, Early Life Nutrition, Fengru Lin, gut health, HMOs, Human Health Biosolutions, Human Milk Oligosaccharides, immunity, Infant Nutrition, iron regulation, lactoferrin, LF+®, Mitsui Chemicals Inc, Novonesis, Novonesis Adds TurtleTree Collaboration to Human Health Biosolutions Portfolio, Novonesis and TurtleTree Join Forces to Expand Commercial Access to Lactoferrin LF+®, Novonesis Invests in TurtleTree as Companies Advance Precision-Fermented Lactoferrin Commercialization, Precision Fermentation, probiotics, synbiotics, Thomas Batchelor, TurtleTree, US FDA GRAS status, US GRAS No Objection Letter, Women’s Health
(IN BRIEF) Scientists at the University of East Anglia have developed a rapid at-home sperm test paired with a mobile app to provide personalised fertility advice and support. The test, created by UEA spin-out Virilitas Labs, is designed to deliver … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Abingdon Health, AI Assistant, at-home fertility test, Biomedical Catalyst, Bourn Hall Fertility Clinic, clinical validation, Dr Daniel Marcu, fertility app, fertility biomarkers, health technology, Innovate UK, lateral flow test, male fertility, male infertility, Norfolk and Norwich University Hospital, Norwich, Norwich Research Park, Professor Simone Immler, reproductive genetics, reproductive health, semen sample, sperm health, sperm motility, sperm test, UEA, UEA Spin-Out Partners With Clinical and Manufacturing Specialists to Advance Male Fertility Testing Platform, United Kingdom, University of East Anglia, Virilitas Labs, Virilitas Labs Develops At-Home Sperm Health Test as Male Fertility Concerns Continue to Rise Globally
(IN BRIEF) University of Liverpool researchers have identified distinctive molecular and biological characteristics in adenomyosis lesions that could help support the development of more targeted treatments for the condition. Using spatial transcriptomics to compare diseased and healthy tissue from the … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged adenomyosis, clinical research, Dr Alison Maclean, energy metabolism, fertility, fertility preservation, gene activity, gynaecology, heavy menstrual bleeding, inflammation, lesion targeting, Liverpool Scientists Map Adenomyosis Lesions in Search for Uterus-Sparing Treatments, Molecular Biology, MRC, New Findings Could Support Less Invasive Treatment Approaches for Women With Adenomyosis, NIHR, non surgical treatment, pelvic pain, Professor Dharani Hapangama, reproductive health, Science Advances, spatial transcriptomics, Study Identifies Biological Signature of Adenomyosis Lesions and Potential Treatment Targets, United Kingdom, University of Liverpool, uterine health, uterine tissue, Women’s Health
(IN BRIEF) The US Food and Drug Administration has accepted and granted Priority Review to Roche’s supplemental Biologics License Application for Enspryng, or satralizumab, in thyroid eye disease. The application is supported by data from the Phase 3 SatraGO-1 and … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland, Technology
Tagged at-home treatment, autoimmune disease, Chugai, clinical activity score, clinical development, diplopia, Enspryng, Enspryng Could Become At-Home Subcutaneous Treatment Option for Thyroid Eye Disease, Enspryng Phase 3 Programme Shows Improvements in Key Thyroid Eye Disease Measures, FDA, FDA Priority Review Supports Roche’s Planned Expansion of Enspryng Into Thyroid Eye Disease, Graves’ ophthalmopathy, IL-6 receptor, Levi Garraway, neuromyelitis optica spectrum disorder, NMOSD, ophthalmology, Phase 3 clinical trial, Priority Review, proptosis, rare disease, regulatory submission, Roche, SatraGO-1, SatraGO-2, satralizumab, sBLA, subcutaneous treatment, supplemental Biologics License Application, TED, thyroid eye disease, US Food and Drug Administration
(IN BRIEF) Sanofi has reported that Nexviazyme met its primary and all secondary endpoints in the Baby-COMET Phase 3 study in treatment-naïve infants with infantile-onset Pompe disease. The primary endpoint assessed the proportion of participants aged six months or younger … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech, Science, Technology
Tagged acid alpha-glucosidase, avalglucosidase alfa, Baby-COMET, Baby-COMET Study Shows Positive Phase 3 Findings for Nexviazyme in Treatment-Naïve Infants, Christopher Corsico, Duke University Medical Center, enzyme replacement therapy, ERT, FDA regulatory submission, Florence, Frontiers in clinical research, GAA enzyme, infantile-onset Pompe disease, inherited neuromuscular disease, International Congress on Neuromuscular Diseases, invasive ventilation, IOPD, late-onset Pompe disease, LOPD, Nexviadyme, Nexviazyme, Nexviazyme Demonstrates Positive Results in Single-Arm Phase 3 Infant Pompe Disease Study, pediatric medicine, pediatric rare disease, Phase 3 clinical trial, Pompe disease, Priya S. Kishnani, rare disease, Sanofi, Sanofi Reports Ventilator-Free Survival Results for Nexviazyme in Infantile-Onset Pompe Disease, ventilator-free survival
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have developed WIN-DOSE, a proposed clinical-trial design to support more transparent and patient-centred selection of cancer drug doses in early-stage studies. The method enables researchers to establish a clear hierarchy … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged cancer drug development, cancer research, Cancer Research UK, Christina Yap, Clinical Cancer Research, clinical trial statistics, clinical trials, dose optimisation, dose selection, Drug Safety, early-stage clinical trials, Emily Alger, ICR, New Statistical Design Aims to Strengthen Evidence-Based Dose Decisions in Cancer Research, oncology, patient-centred research, patient-reported outcomes, Patient-Reported Outcomes Feature in New Framework for Selecting Cancer Drug Doses, pharmacodynamics, pharmacokinetics, precision medicine, The Institute of Cancer Research, treatment efficacy, treatment tolerability, United Kingdom, WIN-DOSE
(IN BRIEF) AstraZeneca and Daiichi Sankyo have secured European Union approval for Enhertu as a tumour-agnostic monotherapy for adults with previously treated HER2-positive IHC 3+ unresectable or metastatic solid tumours who have no satisfactory treatment alternatives. The decision is the … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, Benedikt Westphalen, biomarker testing, breast cancer, cancer treatment, CHMP, colorectal cancer, Daiichi Sankyo, Dave Fredrickson, DESTINY-Breast01, DESTINY-CRC02, DESTINY-Lung01, DESTINY-PanTumor02, EMA, Enhertu, Enhertu Approval Brings HER2-Directed Antibody Drug Conjugate Therapy to Broader Solid Tumour Population, European Commission, European Medicines Agency, gastric cancer, HER2 testing, HER2-positive solid tumours, Ken Keller, metastatic cancer, New EU Enhertu Indication Expands Targeted Treatment Options Beyond Individual Tumour Types, non-small cell lung cancer, objective response rate, oncology, Phase II Evidence Supports EU Tumour-Agnostic Approval of Enhertu for HER2-Positive Cancers, precision oncology, targeted therapy, trastuzumab deruxtecan, tumour-agnostic therapy, unresectable cancer
(IN BRIEF) Evidenze has selected Telefónica to build a healthcare Data Space intended to support clinical research, biomedical analysis and the development of digital health technologies. Developed through Telefónica Tech and Geprom, the platform will allow healthcare stakeholders to share … Read the full press release
Posted in Artificial Intelligence (AI), Business, European Union, Healthcare, Pharma & Biotech, Security & Safety, Spain, Technology
Tagged adverse effects, AI predictive model, anonymised data, artificial intelligence, biomedical research, cancer treatment, Carlos Martínez, clinical data, clinical research, Data Governance, data sharing, data sovereignty, digital health, EHDS, European Health Data Space, Evidenze, Evidenze and Telefónica Develop Oncology Data Use Cases for More Precise Clinical Analysis, Evidenze Data Space, Geprom, healthcare data space, healthcare technology, interoperability, medicine safety, metastatic pancreatic cancer, New Healthcare Data Space Supports Secure Evidence Generation Across Spain’s Health Ecosystem, patient monitoring, patient privacy, Pedro Lisbona, personalised medicine, real-world evidence, Spain, Telefonica, Telefónica Tech, Telefónica Tech Helps Evidenze Advance Privacy-Focused Clinical Research Data Sharing, treatment efficacy
(IN BRIEF) EQT Life Sciences has joined a USD 115 million Series A financing for UK biotechnology company RQ Bio, alongside lead investor Frazier Life Sciences, other new investors and existing backers. The funding will support clinical development of RQB01, … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged antibody discovery, antibody therapies, biopharmaceuticals, biotechnology investment, Christian S. Schade, clinical development, EQT Life Sciences, Felice Verduyn-van Weegen, flu season protection, Forbion, Frazier Life Sciences, Halda Therapeutics, high-risk populations, immunocompromised patients, infectious diseases, influenza prevention, LifeArc, Mike Westby, Monograph, New Series A Financing Supports RQB01 Development for High-Risk Influenza Patients, Oxford Science Enterprises, Oxford University Innovation, preventive therapy, rare and vulnerable patient populations, respiratory viral diseases, RQ Bio, RQ Bio Expands Investor Base and Appoints Christian S. Schade as Executive Chairman, RQ Bio Secures Major Funding Round for Antibody-Based Respiratory Disease Prevention Pipeline, RQB01, seasonal influenza, Series A financing, Wellington Management
(IN BRIEF) Sanofi’s Wayrilz® (rilzabrutinib) has received approval in Japan for the treatment of persistent or chronic immune thrombocytopenia in patients who have not responded sufficiently to other therapies or have tolerability concerns with existing options. The authorization is based … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology
Tagged abdominal pain, bleeding risk, Bruton’s tyrosine kinase inhibitor, BTKi, chronic ITP, clinical research, diarrhoea, durable platelet response, headache, Hisashi Kato, IgG4-related disease, immune thrombocytopenia, ITP, Japan, Japan Approval Adds Wayrilz to Treatment Options for Persistent or Chronic ITP, LUNA 3, Manuela Buxo, Ministry of Health Labour and Welfare, multi-immune modulation, nausea, orphan drug designation, persistent ITP, Phase 3 clinical trial, platelet counts, platelet response, quality of life, rare disease, rilzabrutinib, Sanofi, Sanofi Expands ITP Treatment Portfolio With Wayrilz Approval in Japan, Sanofi’s Wayrilz Receives Japan Approval for Persistent and Chronic Immune Thrombocytopenia, sickle cell disease, specialty care, warm autoimmune haemolytic anaemia, Wayrilz, Wayrilz Approved in Japan Following Positive Phase 3 LUNA 3 Results in Immune Thrombocytopenia
(IN BRIEF) Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective September 1, 2026. Based in Paris and reporting to CEO Belén Garijo, Fontoura will join Sanofi’s Executive Committee and lead … Read the full press release
Posted in Artificial Intelligence (AI), Business, France, Healthcare, Management, Pharma & Biotech, Science
Tagged American Academy of Neurology, artificial intelligence, Belén Garijo, biopharma, breakthrough therapies, clinical development, clinical scientists, drug discovery, EMA approvals, FDA approvals, generative AI, Global Head of R&D Pharma, Houman Ashrafian, immunology, infectious diseases, neuroimmunology, Neurology, neuroscience, new molecular entities, New University of Lisbon, ophthalmology, Paulo Fontoura, Paulo Fontoura to Lead Sanofi’s Global R&D Organisation from September 2026, pharmaceutical innovation, pharmaceutical research and development, physician-scientist, pipeline development, R&D transformation, rare diseases, regulatory affairs, Roche, Sanofi, Sanofi Appoints Paulo Fontoura as Global Head of Pharmaceutical Research and Development, Sanofi Executive Committee, Sanofi Selects Paulo Fontoura to Advance Global Pipeline and AI-Enabled R&D Strategy, Sanofi Strengthens Research and Development Leadership with Paulo Fontoura Appointment, Stanford University, translational medicine, Xaira Therapeutics
(IN BRIEF) Sanofi has received approval from Japan’s Ministry of Health, Labour and Welfare for the subcutaneous formulation of Sarclisa, or isatuximab, in combination with approved standard-of-care regimens for multiple myeloma. The approval covers use with pomalidomide and dexamethasone, or … Read the full press release
Posted in European Union, France, Government, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anemia, anti-CD38 monoclonal antibody, anticancer treatment, bortezomib, cancer treatment, carfilzomib, CirCLIQ on-body injector, COVID-19, dexamethasone, Enable Injections, enFuse platform, European Union, hematologic malignancy, immunological therapies, infusion reactions, injection-site reactions, IRAKLIA phase 3 study, isatuximab, Japan, Japan Approval of Sarclisa Subcutaneous Builds on Phase 3 IRAKLIA Study Results, Japan Approves Sanofi’s Sarclisa Subcutaneous for Newly Diagnosed and Relapsed Multiple Myeloma, Japan Ministry of Health Labour and Welfare, Kd, lenalidomide, manual subcutaneous injection, Multiple Myeloma, NCT05405166, NDMM, neutropenia, newly diagnosed multiple myeloma, non-inferior efficacy, objective response rate, Olivier Nataf, on-body injector, oncology, ORR, Pd, pharmacokinetics, pneumonia, pomalidomide, R/R MM, relapsed or refractory multiple myeloma, Sanofi, Sanofi’s Sarclisa Subcutaneous Approval in Japan Expands Treatment Delivery Options for Multiple Myeloma Patients, Sarclisa, standard-of-care regimens, Subcutaneous formulation, targeted therapies, thrombocytopenia, United States, upper respiratory tract infection, VRd
(IN BRIEF) ZEISS Medical Technology has entered into a strategic collaboration with Envision Health Technologies to advance virtual reality-based visual function testing for glaucoma care. The partnership combines ZEISS’ long-standing expertise in perimetry and visual field testing with Envision’s software-driven … Read the full press release
Posted in Artificial Intelligence (AI), European Union, Germany, Healthcare, Internet & Online, News, Pharma & Biotech, Science, Technology
Tagged Anuj Kalra, Carl Zeiss Meditec AG, chronic disease management, clinical credibility, clinical rigour, clinician-driven innovation, data-driven solutions, digital eye health, Dr Lama A Al-Aswad, Envision Health Technologies, eye health technology, gamified virtual reality, Germany, glaucoma care, glaucoma diagnostics, glaucoma screening, Jena, medical technology, modern glaucoma care, ophthalmology, patient-accessible testing, patient-centred care, perimetry, portable testing, software-driven diagnostics, virtual reality testing, vision-threatening diseases, visual field testing, visual function testing, VR perimetry, ZEISS Advances Digital Glaucoma Testing Strategy Through Collaboration with Envision Health Technologies, ZEISS and Envision Health Technologies Combine Perimetry Expertise and VR Innovation for Eye Care, ZEISS Medical Technology, ZEISS Partnership with Envision Health Technologies Targets Software-Driven Glaucoma Diagnostics
(IN BRIEF) The Institute of Cancer Research, London, has welcomed the US FDA approval of capivasertib for patients with PTEN-deficient advanced prostate cancer, marking the first regulatory approval of the targeted drug in prostate cancer. Capivasertib blocks AKT, a cancer-driving … Read the full press release
Posted in Business, Education, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 3D protein structure, abiraterone, advanced cancer, advanced prostate cancer, AKT inhibitor, AKT pathway, AKT1 mutations, Astex Pharmaceuticals, AstraZeneca, breast cancer, cancer cell growth, cancer cell survival, cancer progression, Cancer Research Technology Limited, Cancer Research UK, CAPItello-281 trial, CAPItello-291 trial, capivasertib, Capivasertib Gains First Prostate Cancer Approval Following Decades of ICR-Led AKT Research, Centre for Cancer Drug Discovery, drug discovery, European Union, FDA, FDA Approval of Capivasertib Marks New Targeted Treatment Option for Advanced Prostate Cancer, fragment-based drug design, fulvestrant, HER2-negative breast cancer, HR-Positive Breast Cancer, ICR, ICR Welcomes FDA Approval of Capivasertib for PTEN-Deficient Advanced Prostate Cancer, ICR Welcomes Milestone FDA Decision for Targeted Therapy in PTEN-Deficient Prostate Cancer, Nature Communications, Nice, oncology research, overall survival, Phase III Trial, PI3 kinase pathway, PIK3CA mutations, precision oncology, Professor Kristian Helin, Professor Paul Workman, prostate cancer patients, prostate cancer treatment, PTEN-deficient prostate cancer, PTEN-deficient tumours, regulatory approval, small molecule inhibitors, targeted therapy, The Institute of Cancer Research, United Kingdom
(IN BRIEF) Thousands of men with early-stage prostate cancer in England will now be offered stereotactic body radiotherapy, also known as stereotactic ablative radiotherapy, through the NHS after results from the PACE-B trial showed the treatment can be as effective … Read the full press release
Posted in Education, Government, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cancer care, cancer recurrence, cancer treatment, clinical research, Clinical Trials and Statistics Unit, early-stage prostate cancer, England, five-session treatment, gastrointestinal side effects, genital and urinary side effects, high-powered radiotherapy, hospital appointments, ICR, ICR and Royal Marsden Trial Supports Faster Radiotherapy Option for Prostate Cancer Patients, IMRT, intensity-modulated radiotherapy, localised prostate cancer, low-risk prostate cancer, medium-risk prostate cancer, NHS England, NHS England Approves SBRT for Eligible Men with Low and Medium-Risk Prostate Cancer, NHS radiotherapy centres, PACE-B trial, Phase III Trial, precision radiotherapy, Professor Emma Hall, Professor Nicholas van As, Professor Peter Johnson, prostate cancer, radiation beams, radiotherapy, randomised trial, SABR, SBRT, Shorter High-Powered Radiotherapy Course Set to Reduce Treatment Burden for Prostate Cancer Patients, stereotactic ablative radiotherapy, stereotactic body radiotherapy, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Thousands of Men in England to Benefit from More Precise Five-Visit Prostate Cancer Radiotherapy, treatment side effects, tumour targeting, United Kingdom
(IN BRIEF) Scientists at The Institute of Cancer Research, London, and the University of Oxford have uncovered a mechanism that helps cancer cells survive radiotherapy by repairing radiation-induced DNA damage. The study found that insulin-like growth factor 1 receptor, or … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Balmus Laboratory, Blocking Cancer Cell Repair Pathway May Strengthen Future Radiotherapy Strategies, Cancer and Genome Instability Group, cancer cell survival, cancer research, Cancer Research UK, cancer therapy, cell survival mechanisms, chromatin, combination treatments, DNA damage response, DNA repair, DNA-dependent protein kinase catalytic subunit, DNA-PKcs, double-strand breaks, Dr Matthew Ellis, Dr Valentine Macaulay, drug targets, end-joining, genome instability, growth signalling, ICR, IGF-1R, insulin-like growth factor 1 receptor, Medical Research Council, Molecular Oncology, New Study Links Cancer Growth Receptor to DNA Repair After Radiation Treatment, non-homologous end joining, oncology, precision treatment, Professor Wojciech Niedzwiedz, prostate cancer, Prostate Cancer UK, radiation treatment, radiotherapy, Research Reveals How IGF-1R Helps Tumours Survive Radiation-Induced DNA Damage, resistant tumours, Targeting IGF-1R Could Make Cancer Cells More Vulnerable to Radiotherapy, The Institute of Cancer Research, treatment resistance, tumour biology, United Kingdom, University of Cambridge, University of Oxford
(IN BRIEF) Evonik is selling selected production assets for pharmaceutical ingredients at its Hanau site in Germany to the ProChem Group, with the transaction expected to close on 19 June 2026. The divestment supports Evonik Health Care’s strategy of streamlining … Read the full press release
Posted in Business, Chemicals, European Union, France, Germany, Healthcare, Industrial, Pharma & Biotech, Science, Technology
Tagged active pharmaceutical ingredients, advanced pharmaceutical lipids, amino acids, analytical testing, APIs, asset streamlining, CDMO services, cell-culture ingredients, contract manufacturing, cosmetics ingredients, distillation, Dr Jürgen Krauter, drug delivery technologies, drying, Essen, Evonik, Evonik Advances Health Care Growth Strategy Through Hanau Production Asset Transfer, Evonik Health Care, Evonik Sells Hanau Pharmaceutical Ingredient Production Assets to ProChem Group, Evonik Streamlines Health Care Footprint with Sale of Selected Hanau Assets to ProChem, extraction, food additives, France, gene delivery, Gerhard Jakobi, Germany, GMP facility, GMP-compliant production, grinding, Guido Skudlarek, Ham, Hanau, healthcare portfolio, injectable drug delivery, Intermediates, Janusz Berger, Jochen Pohl, Jörg Blumhoff, Kerstin Oberhaus, keto acids, mixing, mRNA delivery, oral drug delivery, packaging, pharmaceutical customers, pharmaceutical ingredients, pharmaceutical lipids, pharmaceutical-grade products, precision biosolutions, ProChem Acquires Evonik GMP Production Facilities for Pharmaceutical Ingredients in Hanau, ProChem GmbH, ProChem Group, ProChem InnoTec GmbH, production assets, regulatory-compliant solutions, REXIM, RNA therapeutics, sieving, specialty chemicals, synthesis, Thomas Hermann, Wuming
(IN BRIEF) The Biotechnology and Biological Sciences Research Council is investing £10 million in 21 new Fellows through its Fellowships scheme, supporting early-stage researchers as they move toward independent research leadership. The new cohort will conduct discovery-led research at leading … Read the full press release
Posted in Agriculture, Artificial Intelligence (AI), Education, Environment, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adam Jalal, Alexandra Fletcher-Jones, Anthony Devlin, artificial intelligence, BBSRC, BBSRC Fellowships scheme, BBSRC Funding to Advance Biological Sciences Research Across UK Universities and Institutes, BBSRC Invests in Emerging Research Leaders Tackling Fundamental Questions in Modern Bioscience, BBSRC Supports Discovery Research and Independent Leadership with New Cohort of 21 Fellows, Ben Raymond, Bianca Pierattini, Biological Sciences, biomaterials, bioscience research, biotechnology, Biotechnology and Biological Sciences Research Council, carbon-efficient bioproduction, cell biology, Charlene Dambire, Charlotte Thomas, David Willnow, Deyana Ivanova, discovery research, early-stage researchers, Elizabeth Ledger, engineering biology, Ennio d’Amico, environmental biology, Eva Jimenez Guri, genetics, host-pathogen biology, immune responses, immunology, Imperial College London, independent research leadership, Jack Collier, Jason Woodgate, King’s College London, marine embryos, Micaela Chacon, microbiology, microplastic leachates, Mitochondria, Molecular Biology, MRC Laboratory of Molecular Biology, neuroscience, Newcastle University, Olivia Pedroncini, pathogen detection, Pierce Mullen, plant science, prion diseases, Professor Anne Ferguson-Smith, Rafael Moreno Tortolero, Robert Mason, Rosalind Franklin Institute, RT-QuIC, silk secretion, Stefano Bettinazzi, Tanja Fuchsberger, The Francis Crick Institute, UK Bioscience Research Gains £10 Million Boost Through 21 New BBSRC Fellowships, UK Research and Innovation, UKRI, United Kingdom, University College London, University of Birmingham, University of Bristol, University of Cambridge, University of Edinburgh, University of Exeter, University of Manchester, University of Nottingham, University of St Andrews, University of York, £10 million funding
(IN BRIEF) Roche has announced that the US FDA has accepted its supplemental Biologics License Application for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab, in combination with Polivy for adults with relapsed or refractory large B-cell lymphoma, including diffuse large … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged antibody-drug conjugate, ASCO Annual Meeting, Basel, CD20xCD3 bispecific antibody, CD79b, CELESTIMO, chemotherapy-free regimen, community oncology, crs, cytokine release syndrome, diffuse large B-cell lymphoma, DLBCL, European Hematology Association Congress, FDA, FDA Filing Acceptance Brings Roche’s Chemotherapy-Free Lymphoma Combination Closer to Potential Approval, follicular lymphoma, gemcitabine, haematology, LBCL, Levi Garraway, Lunsumio, Lunsumio VELO, Lunsumio VELO and Polivy Combination Shows 59 Percent Risk Reduction in Roche’s FDA Filing for LBCL, lymphoma care, Lymphoma Research Foundation, MabThera®, Meghan Gutierrez, Mission Cancer and Blood, MorningLyte, mosunetuzumab, Non-Hodgkin lymphoma, outpatient-ready treatment, oxaliplatin, PFS, Phase III Trial, polatuzumab vedotin, Polivy, progression-free survival, R-GemOx, relapsed or refractory large B-cell lymphoma, Rituxan, rituximab, Roche, Roche Reports FDA Acceptance of sBLA Based on SUNMO Study Results in Relapsed or Refractory Large B-Cell Lymphoma, sBLA, SUNMO study, supplemental Biologics License Application, Switzerland, T-cell engaging bispecific antibody, Tara M Graff
(IN BRIEF) Accenture has agreed to acquire Industries eXcellence Group, a division of Engineering Group and long-standing Siemens Digital Industries partner, to strengthen its capabilities in industrial software, automation, data and AI-enabled manufacturing transformation. IndX specialises in Siemens technologies for … Read the full press release
Posted in Artificial Intelligence (AI), Automotive, Aviation & Aerospace, Business, Defence, Electronics & Machinery, Energy, Gas & Oil, European Union, Government, Healthcare, Industrial, Infrastructure & Utilities, Ireland, Italy, Management, Pharma & Biotech, Technology
Tagged Accenture, Accenture Plans New Siemens Digital Industries Centers of Excellence Following Industries eXcellence Group Acquisition, Accenture Siemens Business Group, Accenture Targets Smarter Engineering, Aerospace and Defence, AI-enabled technologies, artificial intelligence, automation solutions, automotive, Center of Excellence, Chicago, cloud computing, consumer goods, data, digital manufacturing, Digital Thread, Digital Twins, discrete manufacturing, ENERGY, engineering group, engineering operations, factory operations, Factory Operations and Supply Chains with IndX Acquisition, Germany, high tech, INDIA, industrial AI, industrial edge computing, industrial equipment, industrial software, Industries eXcellence Group, IndX, information technology, Italy, life sciences, manufacturing transformation, Mexico, operational technology, PLM, process manufacturing, Product Lifecycle Management, Rome, SCADA, Siemens Digital Industries, Siemens Digital Industries Software, simulation, Supervisory Control and Data Acquisition, supply chain operations, Teodoro Lio, Tony Hemmelgarn, Tracey Countryman, utilities, Vivek Kaushik
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?